Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Market Cap	7.66B -14.0%
Revenue (ttm)	1.41B +3.8%
Net Income	-14.34M
EPS	-0.03
Shares Out	397.73M
PE Ratio	n/a
Forward PE	63.18
Dividend	0.50 (2.61%)
Ex-Dividend Date	Jun 3, 2026

Volume	2,089,698
Open	19.07
Previous Close	19.13
Day's Range	18.91 - 19.50
52-Week Range	18.17 - 26.77
Beta	0.74
Analysts	Strong Buy
Price Target	26.74 (+38.77%)
Earnings Date	Aug 28, 2026

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 3,002
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688105

Financial Performance

In 2025, Nanjing Vazyme Biotech's revenue was 1.38 billion, a decrease of -0.00% compared to the previous year's 1.38 billion. Losses were -16.61 million, -8.18% less than in 2024.